New Products

MISSISSAUGA, Ontario — Nuvo Research on Friday announced that the U.S. Food and Drug Administration approved Mallinckrodt's new drug application for Pennsaid (diclofenac sodium topical solution) 2%.

MOUNTAIN VIEW, Calif. — Google is testing a smart contact lens that’s built to measure glucose levels in tears using a tiny wireless chip and miniaturized glucose sensor that are embedded between two layers of soft contact lens material, according to a blog outlining the project posted Thursday. 

HERSHEY, Pa. — Hershey on Wednesday announced that it's launching a new line of chocolate spreads, called Hershey's Spreads. The spreads will be available in three varieties: Chocolate, Chocolate with Almond and Chocolate with Hazelnut. 

ST. LOUIS — MidWest Gloves & Gear — a manufacturer of garden accessories, lawn and garden footwear, boots and rainwear — has introduced a licensed line of "Teenage Mutant Ninja Turtles" garden gloves and accessories. The MidWest Ninja Turtles Garden Gloves and Gear lineup includes Gripping and Jersey Garden Gloves, Bucket Hat, Watering Can, Garden Bucket, Kneeling Pad and Garden Trowel and Cultivator.    

DALLAS — Kimberly-Clark's Depend brand has introduced a discreet incontinence solution. New Fit-Flex protection allows men and women to be as active as they want to be without fear of embarrassment, according to the company.

MINNEAPOLIS — Target is gearing up for spring with the launch of new Sonia Kashuk makeup, beauty tools and cosmetic bags available exclusively at Target beginning in March.

This season, the makeup artist, who has had a creative partnership with Target since 1999, is bringing to her collection new formulas for flawless skin, luxe metallic shadows and bold brights for lips and cheeks. New eye and facial makeup includes:

ENGLEWOOD CLIFFS, N.J. — Unilever’s Dove Hair is celebrating the launch of its new Dove Advanced Hair Series collection with a three-day salon event at the film festival in Park City, Utah.

WHITEHOUSE STATION, N.J. — Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar. Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.